read
great
interest
articl
khan
et
al
report
result
pilot
clinic
trial
administr
recombin
angiotensinconvert
enzym
patient
acut
respiratori
distress
syndrom
ard
current
research
focus
involv
reninangiotensin
system
ra
pathogenesi
clinic
outcom
ard
particular
evalu
angiotensinconvert
enzym
ace
angiotensin
ii
ang
ii
ang
ii
receptor
type
axi
counterpart
receptor
pathway
potenti
therapeut
target
given
lack
effect
pharmacolog
ard
treatment
clinic
trial
explor
new
therapeut
strategi
like
khan
et
al
essenti
associ
ace
activ
ard
outcom
far
linear
multipl
factor
like
heterogen
ard
variabl
ra
activ
patient
subgroup
could
implic
complex
interplay
even
though
increas
level
ace
ang
ii
detect
patient
ard
pathophysiolog
role
ra
ard
develop
remain
unclear
addit
factor
exampl
variabl
substrat
ace
apart
ang
name
bradykinin
apelin
protect
effect
lung
injuri
ang
ii
receptor
type
exert
effect
via
receptor
via
ang
ii
receptor
type
could
implic
encourag
data
anim
model
posit
effect
ard
respect
data
involv
human
insuffici
studi
higher
ace
level
associ
oxygen
index
even
though
dd
genotyp
relat
higher
serum
ace
level
seem
correl
ard
prognosi
zambelli
et
al
show
improv
arteri
oxygen
although
clinic
relev
experiment
ard
model
administr
angiotensin
differ
surviv
pulmonari
mechan
khan
et
al
studi
administr
recombin
ard
patient
decreas
ang
ii
level
without
caus
hypotens
worsen
respiratori
mechan
khanna
et
al
demonstr
ang
ii
administr
patient
vasodilatori
shock
increas
blood
pressur
without
rais
risk
ard
appar
variabl
often
conflict
data
current
literatur
complex
associ
ra
ard
warrant
conduct
addit
clinic
trial
elucid
pathophysiolog
background
evalu
potenti
new
treatment
grate
comment
vrigkou
et
al
share
view
regard
need
investig
ra
biolog
ard
acut
ill
patient
addit
welldocu
effect
vascular
tone
fluidelectrolyt
homeostasi
classic
ra
system
action
ang
ii
receptor
angiotensin
receptor
elicit
inflamm
oxid
stress
cellular
apoptosi
fibroprolif
respons
import
compon
ard
pathophysiolog
shown
improv
pathophysiolog
outcom
variou
anim
model
ard
reduc
ang
signal
activ
regulatori
angiotensin
pathway
demonstr
studi
administ
angiotensin
peptid
alon
relat
genet
evid
support
role
ra
human
ard
agre
vrigkou
et
al
data
somewhat
contradictori
probabl
heterogen
within
ard
cohort
hamper
interpret
genet
associ
studi
despit
limit
data
metaanalys
suggest
associ
dallel
ace
gene
ard
risk
mortal
togeth
work
elucid
receptor
sever
acut
respiratori
syndrom
sar
coronaviru
caus
uncharacterist
sever
lung
injuri
associ
profound
deplet
data
suggest
import
role
ard
pathophysiolog
pilot
clinic
trial
design
establish
preliminari
safeti
toler
emphasi
monitor
hemodynam
stabil
defin
exposurerespons
relationship
ra
system
mention
discuss
reader
exercis
caution
interpret
effect
studi
treatment
physiolog
respiratori
mechan
given
small
sampl
size
risk
ascertain
bia
later
time
point
small
number
patient
contribut
point
estim
signific
imbal
group
appar
final
contrast
trial
ang
ii
infus
elicit
acut
improv
map
patient
highoutput
shock
import
rather
reveal
novel
protect
role
ang
ii
via
receptor
believ
confirm
wellestablish
vasopressor
effect
ang
ii
mediat
via
rationalis
whether
classic
ra
signal
benefici
harm
acut
ill
patient
trial
ang
ii
requir
fulli
understand
longerterm
safeti
profil
impact
ra
biolog
system
impact
organ
failur
outcom
meantim
specul
may
place
therapi
differ
patient
popul
shortterm
replet
ang
ii
certain
vasopleg
shock
patient
low
ang
ii
level
replet
ard
patient
high
ang
iiangiotensin
ratio
abbrevi
ace
angiotensinconvert
enzym
angiotensinconvert
enzym
ang
ii
angiotensin
ii
ard
acut
respiratori
distress
syndrom
ra
reninangiotensin
system
